Immunohistochemical and genetic profiles of endometrioid endometrial carcinoma arising from atrophic endometrium

Geels, Yvette P.; Putten, Louis J.M. van der; Tilborg, Angela A.G. van; Lurkin, Irene; Zwarthoff, Ellen C.; Pijnenborg, Johanna M.A.; Erp, Saskia H. van den Berg-van; Snijders, Marc P.L.M.; Bulten, Johan; Visscher, Daniel W.; Dowdy, Sean C.; Massuger, Leon F.A.G.

doi:10.1016/j.ygyno.2015.03.007

Cited by 17 publications

(16 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most frequently mutated genes included PTEN , ARID1A and PIK3CA . This is in line with previously reported frequencies between 37 and 61% for PTEN , 23 and 40% for ARID1A and 24 and 39% for PIK3CA in EC . POLE and TP53 were mutated in 12 and 31% of all cases.…”

Section: Discussionsupporting

confidence: 93%

“…This is in line with previously reported frequencies between 37 and 61% for PTEN, 23 and 40% for ARID1A and 24 and 39% for PIK3CA in EC. [22][23][24][25][26][27][28][29][30][31][32] POLE and TP53 were mutated in 12 and 31% of all cases. Earlier studies found similar frequencies for POLE (7-9.3%), and slightly lower rates of TP53-mutations (12.2-18%).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Mutational analysis of cervical cytology improves diagnosis of endometrial cancer: A prospective multicentre cohort study

Reijnen

Putten

Bulten

et al. 2019

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

Endometrial carcinoma (EC) is traditionally diagnosed by a histopathological assessment of an endometrial biopsy, leaving up to 30% of patients undiagnosed due to technical failure or an inadequate amount of tissue. The aim of the current study is to assess whether mutational analysis of cervical cytology or pipelle endometrial biopsies improves the diagnostic accuracy of traditional histopathological diagnosis of EC. This prospective multicentre cohort study included patients surgically treated for EC or a benign gynaecological condition (control group). A Pap brush sample, cervicovaginal self‐sample, pipelle endometrial biopsy and surgical specimen of either the EC or normal endometrium were obtained. A targeted next‐generation sequencing panel was used to analyse these samples for mutations in eight genes. Sensitivity, specificity and predictive values were calculated. Fifty‐nine EC patients and 31 control patients were included. In these patients, traditional histopathological diagnosis by pipelle had a sensitivity of 79% and a specificity of 100%. For EC patients, 97% of surgical specimens contained at least one mutation. Mutational analysis of Pap brush samples, self‐samples and pipelle endometrial biopsies yielded a sensitivity of 78, 67 and 96% with a specificity of 97, 97 and 94%, respectively. Combining one of these three methods with histopathological pipelle endometrial biopsy evaluations yielded a sensitivity of 96, 93 and 96%, respectively. Our study has shown that mutational analysis of either cervical cytology or pipelle endometrial biopsies improves diagnosis of EC. Prospective validation will support implementation in clinical practice.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 99%

Mutational analysis of cervical cytology improves diagnosis of endometrial cancer: A prospective multicentre cohort study

Reijnen

Putten

Bulten

et al. 2019

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…For each antibody, negative control studies were performed without the primary antibody. Previous reports confirmed that these antibodies showed immunoreactivity for each protein in EC [13,14] . The percentage of positive cells was scored as follows: 1, less than 1% of the nuclei stained; 2, 1-10% of nuclei stained; 3, 10-33% of the nuclei stained; 4, 34-66% of nuclei stained; and 5, more than 67% of the nuclei stained.…”

Section: Immunohistochemical Staining and Interpretationsupporting

confidence: 60%

Small Foci of Serous Component as a Predictor of Recurrence and Prognosis for Stage IA Endometrial Carcinomas

Miyamoto

Takano²,

Tsuda³

et al. 2017

Oncology

View full text Add to dashboard Cite

Objective: Most of the endometrial carcinomas are detected in early stages and have a better prognosis; however, predictive factors for recurrence have not been determined. Methods: Patients with grade 1 endometrioid carcinoma (EG1) according to the 2014 WHO criteria at FIGO 2009 stage IA that were identified through scanning medical charts were included, and we assessed whether the presence of uterine serous carcinoma (SC) component which comprised less than 5% of the total volume using the ovarian two-tiered grading system could be a recurrent risk factor in these patients. Results: Among 126 cases which met inclusion criteria, 12 cases had SC. SC tumors were divided into 2 groups: SC resembling high-grade serous carcinoma (HGSC) and SC resembling low-grade serous carcinoma (LGSC). Five (3.9%) cases had HGSC and 7 (5.6%) cases had LGSC. Recurrence was observed in 3 of all cases (2.3%): 2 cases with HGSC, and 1 case with LGSC. Regarding several clinicopathological factors, only the presence of SC was associated with recurrence. The sensitivity and specificity to predict recurrence using this system were 100 and 93%, respectively. Conclusion: The identification of SC using the ovarian two-tiered grading system could be an accurate predictor of recurrence in stage IA EG1.

show abstract

“…Finally, two recently characterized promising biomarkers were included: L1-cell adhesion molecule (L1CAM) and ʟ-asparaginase like 1 (ASRGL1). The prognostic value of L1CAM has been shown in various settings, both in type I and II EC [2,[13][14][15][16][17][18] and it has attained an established role in EC biomarker panels both in retrospective and prospective studies. ASRGL1 is a novel biomarker candidate, which we recently demonstrated to have an independent prognostic value in two independent EEC cohorts [19] and the prognostic role of ASRGL1 was confirmed in a recent study [20].…”

Section: Introductionmentioning

confidence: 99%

Combined ASRGL1 and p53 immunohistochemistry as an independent predictor of survival in endometrioid endometrial carcinoma

Huvila

Laajala

Edqvist

et al. 2018

Gynecologic Oncology

View full text Add to dashboard Cite

show abstract

Immunohistochemical and genetic profiles of endometrioid endometrial carcinoma arising from atrophic endometrium

Cited by 17 publications

References 38 publications

Mutational analysis of cervical cytology improves diagnosis of endometrial cancer: A prospective multicentre cohort study

Mutational analysis of cervical cytology improves diagnosis of endometrial cancer: A prospective multicentre cohort study

Small Foci of Serous Component as a Predictor of Recurrence and Prognosis for Stage IA Endometrial Carcinomas

Combined ASRGL1 and p53 immunohistochemistry as an independent predictor of survival in endometrioid endometrial carcinoma

Contact Info

Product

Resources

About